Hyung Ju C Shin
Overview
Explore the profile of Hyung Ju C Shin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
469
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jiang N, Wang D, Hu Z, Shin H, Qian G, Rahman M, et al.
Mol Cancer Ther
. 2014 Apr;
13(7):1826-36.
PMID: 24748655
The EGFR monoclonal antibody cetuximab is the only approved targeted agent for treating head and neck squamous cell carcinoma (HNSCC). Yet resistance to cetuximab has hindered its activity in this...
2.
Wang X, Beitler J, Wang H, Lee M, Huang W, Koenig L, et al.
PLoS One
. 2014 Mar;
9(2):e86369.
PMID: 24586249
Resistance to chemotherapy remains a major obstacle in cancer therapy. This study aimed to evaluate the molecular mechanism and efficacy of honokiol in inducing apoptosis and enhancing paclitaxel chemotherapy in...
3.
Saba N, Hurwitz S, Kono S, Yang C, Zhao Y, Chen Z, et al.
Cancer Prev Res (Phila)
. 2013 Oct;
7(3):283-91.
PMID: 24085777
Epidermal growth factor receptor (EGFR) and COX-2 inhibitors synergistically inhibit head and neck squamous cell carcinoma tumorigenesis in preclinical studies. We conducted a phase I and pharmacokinetic study with the...
4.
Shin D, Zhang H, Saba N, Chen A, Nannapaneni S, Amin A, et al.
Clin Cancer Res
. 2013 Feb;
19(5):1244-56.
PMID: 23422093
Purpose: We investigated the efficacy and underlying molecular mechanism of a novel chemopreventive strategy combining EGF receptor (EGFR) tyrosine kinase inhibitor (TKI) with cyclooxygenase-2 inhibitor (COX-2I). Experimental Design: We examined...
5.
Zhang H, Yun S, Batuwangala T, Steward M, Holmes S, Pan L, et al.
Int J Cancer
. 2011 Sep;
131(4):956-69.
PMID: 21918971
An antibody simultaneously targeting epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), two major tumor growth-driving machineries, may provide a novel effective strategy for optimizing tumor targeting...
6.
Hurwitz S, Zhang H, Yun S, Batuwangala T, Steward M, Holmes S, et al.
Cancer Chemother Pharmacol
. 2011 Sep;
69(3):577-90.
PMID: 21913035
Purpose: DT-IgG is a fully humanized dual-target therapeutic antibody being developed to simultaneously target epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), important signaling molecules for tumor...
7.
Wang X, Qian X, Beitler J, Chen Z, Khuri F, Lewis M, et al.
Cancer Res
. 2011 Jan;
71(5):1526-32.
PMID: 21212408
The detection and characterization of circulating tumor cells (CTC) holds great promise for personalizing medicine and optimizing systemic therapy. However, low specificity, low sensitivity, and the time consuming nature of...
8.
Amin A, Wang D, Zhang H, Peng S, Shin H, Brandes J, et al.
J Biol Chem
. 2010 Sep;
285(45):34557-65.
PMID: 20826787
Natural dietary agents have drawn a great deal of attention toward cancer prevention because of their wide safety margin. However, single agent intervention has failed to bring the expected outcome...
9.
Wang X, Li J, Wang Y, Cho K, Kim G, Gjyrezi A, et al.
ACS Nano
. 2009 Sep;
3(10):3165-74.
PMID: 19761191
Nonspecific distribution of chemotherapeutic drugs (such as paclitaxel) is a major factor contributing to side effects and poor clinical outcomes in the treatment of human head and neck cancer. To...
10.
Saba N, Choi M, Muller S, Shin H, Tighiouart M, Papadimitrakopoulou V, et al.
Cancer Prev Res (Phila)
. 2009 Sep;
2(9):823-9.
PMID: 19737986
Inhibition of cyclooxygenase-2 (COX-2) pathways may have significant implications for the prevention and treatment of head and neck squamous cell carcinoma (HNSCC). COX-2 is overexpressed in both premalignant lesions and...